RACK1 and cancer: Our systematic review and meta-analysis demonstrated from an evidence-based medical perspective that RACK1 is a relatively global marker of poor prognosis in patients with cancer; particularly, high RACK1 expression was indicated to be significantly associated with poorer survival (OS and DFS/RFS) and worse clinicopathological characteristics (lymphatic invasion/N+ stage).